ArticleFrontiers in oncology2025

Efficacy and safety of the S-1, nab-paclitaxel, and gemcitabine triplet regimen in patients with resected pancreatic ductal adenocarcinoma.

Donghui Ran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.